Literature DB >> 23417116

Nestin is highly expressed in advanced-stage melanomas and neurotized nevi.

Michiko Akiyama1, Yoko Matsuda, Toshiyuki Ishiwata, Zenya Naito, Seiji Kawana.   

Abstract

Nestin, a class VI intermediate filament protein, was originally described as a neural stem cell/progenitor cell marker. Expression of nestin has been reported to be associated with the migration and metastasis of various types of tumor. In the present study, we examined the expression of nestin in malignant melanomas and nevi. Immunohistochemically, nestin was detected in all compound nevi, but not in the majority of junctional nevi. Nestin was expressed at particularly high levels in nevi with neurotization. In melanoma, nestin was expressed in all T3 and T4 cases, but only in half of the cases of T2 or less severe disease. These results indicate that the expression levels of nestin in melanoma are associated with advanced disease. In conclusion, nestin was expressed in advanced melanoma tissues and neurotized nevi. Nestin may be an important marker of melanocytic neoplasms. Further studies are required to elucidate the regulatory mechanisms of nestin expression and to examine the possibility of nestin-targeted therapy for malignant melanomas.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23417116     DOI: 10.3892/or.2013.2287

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

1.  Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells.

Authors:  Marisa Schmitt; Tobias Sinnberg; Nicolas C Nalpas; Annika Maass; Birgit Schittek; Boris Macek
Journal:  Mol Cell Proteomics       Date:  2019-03-19       Impact factor: 5.911

2.  BRAF and MEK inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors.

Authors:  Deon B Doxie; Allison R Greenplate; Jocelyn S Gandelman; Kirsten E Diggins; Caroline E Roe; Kimberly B Dahlman; Jeffrey A Sosman; Mark C Kelley; Jonathan M Irish
Journal:  Pigment Cell Melanoma Res       Date:  2018-06-28       Impact factor: 4.693

3.  Clinicopathological characteristics of malignant melanomas of the skin and gastrointestinal tract.

Authors:  Michiko Akiyama; Yoko Matsuda; Tomio Arai; Hidehisa Saeki
Journal:  Oncol Lett       Date:  2018-06-06       Impact factor: 2.967

4.  Classification and Grading of Melanocytic Lesions in a Mouse Model of NRAS-driven Melanomagenesis.

Authors:  Charles-Antoine Assenmacher; Sara F Santagostino; Mark A Oyama; Jean-Christophe Marine; Elise Bonvin; Enrico Radaelli
Journal:  J Histochem Cytochem       Date:  2020-12-07       Impact factor: 2.479

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.